Publications by authors named "David Vesole"

Claim this Profile
P
Peripheral Blood Tumor Associated Cell-Free DNA Testing as a Predictor for Relapse Postallogeneic Stem Cell Transplant for Acute Myelogenous Leukemia.
Vanisha Patel, Maciej Kabat, Andrew Ip, Sukhdeep Kaur, Hyung Chan Suh, David Vesole

Transplant Cell Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.
Lindsay Fogel, Patrick C Roney, Jaeil Ahn, Adolfo Aleman, Fideliza Perez-Manon, David Vesole

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma.
Noa Biran, Eli Zolotov, David Vesole, Harsh Parmar, Pooja Phull

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world data.
Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, Divaya Bhutani, David H Vesole

Br J Haematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic versus autologous stem cell transplantation after relapsing following first line autologous transplantation for multiple myeloma: A systematic review.
Heinz Ludwig, Sarah Bernhard, Takashi Ikeda, Cesar O Freytes, Martin Schreder, David H Vesole

Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702.
Rahul Banerjee, Amber R Fritz, Othman S Akhtar, Ciara L Freeman, Andrew J Cowan, David H Vesole

Leukemia· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors and clinical characteristics of patients with newly diagnosed non-secretory multiple myeloma in the era of new drugs in "real-world" study: Experiences of the Polish Myeloma Group.
Grzegorz Charliński, Aneta Szudy-Szczyrek, Martyna Podgajna, Michał Mielnik, Anna Kopińska, David H Vesole

Adv Clin Exp Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax in the Treatment of Multiple Myeloma: A Retrospective Analysis of 79 Patients.
Eli Zolotov, Vanisha Patel, Yedidyah Weiss, Noa Biran, Pooja Phull, David H Vesole

Eur J Haematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective, Randomized, Comparative Study of Myeloablative Fludarabine/Busulfan and Fludarabine/Busulfan/Total Body Irradiation Conditioning in Myeloid Diseases.
Hyung C Suh, Scott D Rowley, Sukhdeep Kaur, Brittany Lukasik, Phyllis McKiernan, David H Vesole

Cancers (Basel)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost.
Ayrton Bangolo, Samir Oza, Ronit Reich-Slotky, Aimee Chappell, David S Siegel, David H Vesole

Curr Stem Cell Res Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-ASCT consolidation with elotuzumab, lenalidomide, and dexamethasone or elotuzumab, pomalidomide, and dexamethasone in high-risk and ultra-high-risk multiple myeloma: a retrospective single-center study.
Eli Zolotov, Maciej Kabat, Harsh Parmar, Palka Anand, Joshua Zenreich, David H Vesole

Leuk Lymphoma· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression.
Charalampos Charalampous, Kimberley Doucette, Aimee Chappell, David H Vesole

Leuk Lymphoma· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Autologous Stem Cell Transplantation in Systemic Light Chain Amyloidosis.
Harsh Parmar, Kimberley Doucette, David Vesole

Clin Lymphoma Myeloma Leuk· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Allogeneic Stem Cell Transplant on Safety and Outcomes of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Patients with Multiple Myeloma (MM).
Ayrton Bangolo, Behzad Amoozgar, Lili Zhang, Vignesh K Nagesh, Imranjot Sekhon, David Vesole

J Clin Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.
Marcelo C Pasquini, Paul K Wallace, Brent Logan, Manmeet Kaur, Joseph D Tario, David H Vesole

J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment-67 Patients Multicenter Analysis.
Grzegorz Charliński, Maximilian Steinhardt, Leo Rasche, Veronica Gonzalez-Calle, Camila Peña, David H Vesole

Cancers (Basel)· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients.
Irit Avivi, David H Vesole, Julio Davila-Valls, Lidia Usnarska-Zubkiewicz, Magdalena Olszewska-Szopa

Cancers (Basel)· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
POEMS Syndrome-Clinical Picture and Management. Current Knowledge.
Artur Jurczyszyn, Magdalena Olszewska-Szopa, David Vesole

Clin Lymphoma Myeloma Leuk· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Naresh Bumma, Binod Dhakal, Raphael Fraser, Noel Estrada-Merly, Kenneth Anderson, David H Vesole

Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.
Brittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, Noel Estrada-Merly, Lohith Gowda, David H Vesole

Blood Adv· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hospital facility characteristics and socioeconomic factors on outcomes and treatment in patients with multiple myeloma: National Cancer Database analysis.
Kimberley Doucette, Allison O Taylor, Bryan Chan, Xiaoyang Ma, Jaeil Ahn, David H Vesole

Ann Hematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interaction between age and gender on survival outcomes in extramedullary multiple myeloma over the past two decades.
Ayrton I Bangolo, Pierre Fwelo, Chinmay Trivedi, Sowmya Sagireddy, Hamed Aljanaahi, David H Vesole

World J Clin Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Current State of Knowledge About Evolution of Multiple Myeloma to Plasma Cell Leukemia.
Artur Jurczyszyn, Magdalena Olszewska-Szopa, David H Vesole

Clin Lymphoma Myeloma Leuk· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a 6-Week Cycle of Nordic Walking Training on Vitamin 25(OH)D Calcium-Phosphate Metabolism and Muscle Damage in Multiple Myeloma Patients-Randomized Controlled Trial.
Olga Czerwińska-Ledwig, David H Vesole, Anna Piotrowska, Joanna Gradek, Wanda Pilch

J Clin Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients.
Sarvarinder K Gill, Rashmi Unawane, Shuqi Wang, Jaeil Ahn, Adolfo Aleman, David H Vesole

Blood Cancer J· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis